BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 17093289)

  • 1. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.
    Tsimikas S; Brilakis ES; Lennon RJ; Miller ER; Witztum JL; McConnell JP; Kornman KS; Berger PB
    J Lipid Res; 2007 Feb; 48(2):425-33. PubMed ID: 17093289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events.
    Prasad A; Clopton P; Ayers C; Khera A; de Lemos JA; Witztum JL; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1213-1221. PubMed ID: 28473443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.
    Ravandi A; Boekholdt SM; Mallat Z; Talmud PJ; Kastelein JJ; Wareham NJ; Miller ER; Benessiano J; Tedgui A; Witztum JL; Khaw KT; Tsimikas S
    J Lipid Res; 2011 Oct; 52(10):1829-36. PubMed ID: 21821825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease.
    Soto Y; Conde H; Aroche R; Brito V; Luaces P; Nasiff A; Obregón A; Vázquez López AM
    Hum Antibodies; 2009; 18(3):109-17. PubMed ID: 19729805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
    Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
    J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
    Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
    J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
    Tsimikas S; Bergmark C; Beyer RW; Patel R; Pattison J; Miller E; Juliano J; Witztum JL
    J Am Coll Cardiol; 2003 Feb; 41(3):360-70. PubMed ID: 12575961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
    Mayr M; Kiechl S; Tsimikas S; Miller E; Sheldon J; Willeit J; Witztum JL; Xu Q
    J Am Coll Cardiol; 2006 Jun; 47(12):2436-43. PubMed ID: 16781371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
    Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
    J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis.
    Cvetkovic JT; Wållberg-Jonsson S; Ahmed E; Rantapää-Dahlqvist S; Lefvert AK
    Rheumatology (Oxford); 2002 Sep; 41(9):988-95. PubMed ID: 12209031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between oxidized LDL, IgM, and IgG autoantibodies to ox-LDL levels with recurrent cardiovascular events in Swedish patients with previous myocardial infarction.
    Crisby M; Henareh L; Agewall S
    Angiology; 2014 Nov; 65(10):932-6. PubMed ID: 24288363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
    Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
    McDowell A; Young IS; Wisdom GB
    J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy.
    Asciutto G; Dias NV; Edsfeldt A; Alm R; Fredrikson GN; Gonçalves I; Nilsson J
    Atherosclerosis; 2015 Apr; 239(2):289-94. PubMed ID: 25682025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
    Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
    Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies against oxidized low-density lipoprotein and lipid profile in patients with chronic periaortitis: case-control study.
    van Bommel EF; van Tits LJ; van den Berg EA; Prins J; Stalenhoef AF
    Rheumatol Int; 2011 Feb; 31(2):201-8. PubMed ID: 20012624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary Events.
    Björkbacka H; Alm R; Persson M; Hedblad B; Nilsson J; Fredrikson GN
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):765-71. PubMed ID: 26916732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.